检索结果-南通市图书馆

Some Observations and Thoughts about Reconfigurable Intelligent Surface Application for 5G Evolution and 6G

ZTE Communications 2022年第1期20卷 14-20页

作者： HOU Xiaolin LI Xiang WANG Xin CHEN Lan suyama satoshi DOCOMO Beijing Communications Laboratories Co. Ltd.Beijing 100190China NTT DOCOMO INC.Tokyo 239-8536Japan

Reconfigurable intelligent surface(RIS)is one of the hottest research topics for 5G evolution and *** is expected that RIS can improve the system capacity and coverage with low cost and power *** paper first discusses typical applications of RIS for 5G evolution and 6G,including RIS-aided smart channels and RIS-aided mega multiple-input multiple-output(MIMO).Then,several observa-tions from RIS trials and system-level simulations are presented,especially those on the deployment strategy and the potential performance gain of RIS for coverage *** near-field effect and a two-step dynamic RIS beamforming method are also ***,we summarize the challenges and opportunities of the RIS technology for 5G evolution and 6G,including hardware design,system and channel modeling,algorithm design and optimization,and *** also suggest a step-by-step commercialization strategy as a conclusion.

关键词： 5G evolution 6G beamforming coverage RIS

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Efficacy and Safety of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma

引用

Journal of Cancer Therapy 2011年第3期2卷 335-341页

作者： Takahito suyama Takeshi Ueda satoshi Fukasawa Atsushi Komaru Masayuki Kobayashi Yukio Naya Naoki Nihei Tomohiko Ichikawa 不详

Objective: This study aim to assess the efficacy and safety of sunitinib in Japanese patients with metastatic renal cell carcinoma (mRCC) in general clinical practice. Patients and Methods: Non-selected fifty eight Japanese patients with mRCC were treated with sunitinib. Overall survival (OS) and time to treatment failure (TTF) were estimated. Response rate and safety profiles were also assessed. Results: Partial response, stable disease, and progressive disease were observed in 13 (22.4%), 26 (44.8%), and 19 (32.8%) patients, respectively. The median TTF was 5.4 months, and the median OS was 11.2 months. In the prior nephrectomy group, the median TTF was 9.0 months, and the median OS was 16.4 months. In the non-nephrectomy group, the median TTF was 1.1 months, and the median OS was 2.8 months. The most frequently occurring Grade 3/4 adverse events (AEs) were anorexia (17.2%), fatigue (12.1%), thrombocytopenia (13.8%), and anemia (12.1%). Conclusions: Sunitinib has a favorable risk/benefit profile in Japanese mRCC patients with a history of nephrectomy.

关键词： Renal Cell Carcinoma Metastasis Sunitinib Adverse Event

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：